Breaking News, Promotions & Moves

Galapagos CFO and COO Thad Huston Departs August 1

Huston has decided to leave the company and return to the U.S. for personal and professional reasons.

By: Rachel Klemovitch

Assistant Editor

Galapagos NV, a global biotechnology company, announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. The company expects to announce Huston’s successor in the coming months. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos’ transformation into a cell therapy company. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Paul Stoffels, MD, CEO and Chair of the Board of Directors ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters